The Pivotal Novel Pathogenic Roles of Hyaluronic Acid and its Receptors in Gliomas

Seidu A. Richard, Nii Korley Kortei, Sylvanus Kampo


HA/CD44 as well as HA/RHAMM cross-talks resulted in glioma cell adhesion, mechanosensing, as well as invasive motility. RHAMM was overexpressed in DIPG and may contribute to the diffuse growth pattern and invasion in DIPG just like other forms of gliomas other than CD44. BEHAB/brevican could be a potential biomarker for glioma detection as well as its progression or malignancy.


CD44, DIPG, Hyaluronan, Glioma, Glioblastoma, RHAMM

Full Text:



Laurent, T.C. and J. Fraser, Hyaluronan. The FASEB journal, 1992. 6(7): p. 2397-2404.

Hayen, W., et al., Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. Journal of cell science, 1999. 112(13): p. 2241-2251.

Rooney, P. and S. Kumar, Inverse relationship between hyaluronan and collagens in development and angiogenesis. Differentiation, 1993. 54(3): p. 1-9.

Akiyama, Y., et al., Hyaluronate receptors mediating glioma cell migration and proliferation. Journal of neuro-oncology, 2001. 53(2): p. 115-127.

Bignami, A. and R. Asher, Some observations on the localization of hyaluronic acid in adult, newborn and embryonal rat brain. International journal of developmental neuroscience, 1992. 10(1): p. 45-57.

Zöller, M., CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Journal of molecular medicine, 1995. 73(9): p. 425-438.

Underhill, C., CD44: the hyaluronan receptor. Journal of cell science, 1992. 103(2): p. 293-298.

Isacke, C.M. and H. Yarwood, The hyaluronan receptor, CD44. The international journal of biochemistry & cell biology, 2002. 34(7): p. 718-721.

Culty, M., H.A. Nguyen, and C.B. Underhill, The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. The Journal of cell biology, 1992. 116(4): p. 1055-1062.

Kim, C.-S., et al., Characterization of invading glioma cells using molecular analysis of leading-edge tissue. Journal of Korean Neurosurgical Society, 2011. 50(3): p. 157.

Turley, E., et al., Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. The Journal of Cell Biology, 1991. 112(5): p. 1041-1047.

Thomas, L., et al., CD44H regulates tumor cell migration on hyaluronate-coated substrate. The Journal of cell biology, 1992. 118(4): p. 971-977.

Turley, E., et al., Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Experimental cell research, 1993. 207(2): p. 277-282.

Valkonen, M., et al., Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas. BMC cancer, 2018. 18(1): p. 664.

Asher, R. and A. Bignami, Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Experimental cell research, 1992. 203(1): p. 80-90.

Hall, C.L., et al., Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. The Journal of cell biology, 1994. 126(2): p. 575-588.

Zhigang Lan, Meng Tian, Yong Deng, Chenghong Wang, Yuekang Zhang, RHAMM, A Potential Therapeutic Target, Is Over Expressed in Diffuse Intrinsic Pontine Gliomas. Biomed J Sci & Tech Res, 2019. 23(2).

Dang, A.Q., et al., Using REMBRANDT to paint in the details of glioma biology: Applications for future immunotherapy. Evolution of the molecular biology of brain tumors and the therapeutic implications, 2013: p. 167-200.

Delpech, B., et al., Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. European Journal of Cancer, 1993. 29(7): p. 1012-1017.

Sadeghi, N., et al., Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. American journal of roentgenology, 2003. 181(1): p. 235-241.

Itano, N., Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. Journal of biochemistry, 2008. 144(2): p. 131-137.

Turley, E., Hyaluronan and cell locomotion. Cancer and Metastasis Reviews, 1992. 11(1): p. 21-30.

Hu, B., et al., The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. Journal of Biological Chemistry, 2008. 283(36): p. 24848-24859.

Kim, M.-S., et al., Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer research, 2005. 65(3): p. 686-691.

Fidler, I.J. The role of the organ microenvironment in brain metastasis. in Seminars in cancer biology. 2011. Elsevier.

Kim, Y. and S. Kumar, CD44-mediated adhesion to hyaluronic acid contributes to mechanosensing and invasive motility. Molecular Cancer Research, 2014. 12(10): p. 1416-1429.

West, D.C., et al., Angiogenesis induced by degradation products of hyaluronic acid. Science, 1985. 228(4705): p. 1324-1326.

Slevin, M., S. Kumar, and J. Gaffney, Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. Journal of biological chemistry, 2002. 277(43): p. 41046-41059.

Senbanjo, L.T. and M.A. Chellaiah, CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Frontiers in cell and developmental biology, 2017. 5: p. 18.

Basakran, N.S., CD44 as a potential diagnostic tumor marker. Saudi medical journal, 2015. 36(3): p. 273.

Perschl, A., et al., Role of CD44 cytoplasmic domain in hyaluronan binding. European journal of immunology, 1995. 25(2): p. 495-501.

Okamoto, I., et al., Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. The Journal of cell biology, 2001. 155(5): p. 755-762.

Williams, K., et al., CD44 integrates signaling in normal stem cell, cancer stem cell and (pre) metastatic niches. Experimental biology and medicine, 2013. 238(3): p. 324-338.

Varga, I., et al., Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis. Central European Neurosurgery-Zentralblatt für Neurochirurgie, 2010. 71(04): p. 173-180.

Naor, D., et al., Involvement of CD44, a molecule with a thousand faces, in cancer dissemination, in Hyaluronan in Cancer Biology. 2009, Elsevier. p. 127-146.

Ponta, H., L. Sherman, and P.A. Herrlich, CD44: from adhesion molecules to signalling regulators. Nature reviews Molecular cell biology, 2003. 4(1): p. 33-45.

Tsukita, S., et al., ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. The Journal of cell biology, 1994. 126(2): p. 391-401.

Lokeshwar, V.B., N. Fregien, and L. Bourguignon, Ankyrin-binding domain of CD44 (GP85) is required for the expression of hyaluronic acid-mediated adhesion function. The Journal of cell biology, 1994. 126(4): p. 1099-1109.

Bourguignon, L.Y., et al., CD44v3, 8–10 is involved in cytoskeleton‐mediated tumor cell migration and matrix metalloproteinase (MMP‐9) association in metastatic breast cancer cells. Journal of cellular physiology, 1998. 176(1): p. 206-215.

Yu, Q. and I. Stamenkovic, Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes & development, 1999. 13(1): p. 35-48.

Cao, G., et al., Involvement of endothelial CD44 during in vivo angiogenesis. The American journal of pathology, 2006. 169(1): p. 325-336.

Griffioen, A.W., et al., CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood, The Journal of the American Society of Hematology, 1997. 90(3): p. 1150-1159.

Hofmann, M., et al., Identification of IHABP, a 95 kDa intracellular hyaluronate binding protein. Journal of Cell Science, 1998. 111(12): p. 1673-1684.

Sherman, L., et al., Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Current opinion in cell biology, 1994. 6(5): p. 726-733.

Fieber, C., et al., Characterisation of the murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM). Gene, 1999. 226(1): p. 41-50.

Thorne, R.F., J.W. Legg, and C.M. Isacke, The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. Journal of cell science, 2004. 117(3): p. 373-380.

Zhang, S., et al., The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. Journal of Biological Chemistry, 1998. 273(18): p. 11342-11348.

McCourt, P., et al., Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. Journal of Biological Chemistry, 1994. 269(48): p. 30081-30084.

Nehls, V. and W. Hayen, Are hyaluronan receptors involved in three-dimensional cell migration? Histology and histopathology, 2000. 15(2): p. 629-636.

Gingras, M.-c., et al., Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. Journal of neuroimmunology, 1995. 57(1): p. 143-153.

Choquet, D., D.P. Felsenfeld, and M.P. Sheetz, Extracellular matrix rigidity causes strengthening of integrin–cytoskeleton linkages. Cell, 1997. 88(1): p. 39-48.

McDonald, J., Matrix regulation of cell shape and gene expression. Current opinion in cell biology, 1989. 1(5): p. 995-999.

Xu, Y., I. Stamenkovic, and Q. Yu, CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer research, 2010. 70(6): p. 2455-2464.

Berens, M.E., et al., The role of extracellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay. Clinical & experimental metastasis, 1994. 12(6): p. 405-415.

Couldwell, W.T., et al., Adhesion molecules and malignant gliomas: implications for tumorigenesis. Journal of neurosurgery, 1992. 76(5): p. 782-791.

Rutka, J.T., et al., Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression. Journal of Neuropathology & Experimental Neurology, 1999. 58(2): p. 198-209.

Lesley, J., R. Hyman, and P.W. Kincade, CD44 and its interaction with extracellular matrix, in Advances in immunology. 1993, Elsevier. p. 271-335.

Bartolazzi, A., et al., Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. Journal of Experimental Medicine, 1994. 180(1): p. 53-66.

Günthert, U., et al., A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 1991. 65(1): p. 13-24.

Knüpfer, M.M., et al., CD44 expression and hyaluronic acid binding of malignant glioma cells. Clinical & experimental metastasis, 1999. 17(1): p. 81-86.

Kuppner, M., et al., Differential expression of the CD44 molecule in human brain tumours. International journal of cancer, 1992. 50(4): p. 572-577.

Okada, H., et al., Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells. Cancer Immunology, Immunotherapy, 1994. 39(5): p. 313-317.

Merzak, A., S. Koocheckpour, and G.J. Pilkington, CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer research, 1994. 54(15): p. 3988-3992.

Girgrah, N., C.A. Ackerley, and M.A. Moscarello, Localization of CD44 (P80) on the external surface of a human astrocytoma cell. Neuroreport, 1991. 2(8): p. 441-444.

Baltuch, G.H., N. de Tribolet, and E.G. Van Meir, Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Journal of neuro-oncology, 1995. 26(3): p. 191-198.

Rutka, J.T., et al., Characterization of glial filament-cytoskeletal interactions in human astrocytomas: an immuno-ultrastructural analysis. European journal of cell biology, 1998. 76(4): p. 279-287.

Hall, C.L., et al., Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell, 1995. 82(1): p. 19-28.

Maidment, S., The cytoskeleton and brain tumour cell migration. Anticancer research, 1997. 17(6B): p. 4145-4149.

Xiao, W., A. Sohrabi, and S.K. Seidlits, Integrating the glioblastoma microenvironment into engineered experimental models. Future science OA, 2017. 3(3): p. FSO189.

Nagy, J., et al., Requirement of the hyaluronan receptor RHAMM in neurite extension and motility as demonstrated in primary neurons and neuronal cell lines. Journal of Neuroscience, 1995. 15(1): p. 241-252.

Turley, E., et al., Astrocyte and microglial motility in vitro is functionally dependent on the hyaluronan receptor RHAMM. Glia, 1994. 12(1): p. 68-80.

Pilarski, L.M., et al., RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leukemia & lymphoma, 1994. 14(5-6): p. 363-374.

Abetamann, V., H.F. Kern, and H. Elsässer, Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clinical cancer research, 1996. 2(9): p. 1607-1618.

Warren, K., Diffuse intrinsic pontine glioma: poised for progress. Frontiers in oncology, 2012. 2: p. 205.

Mandell, L.R., et al., There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. International Journal of Radiation Oncology* Biology* Physics, 1999. 43(5): p. 959-964.

Cohen, K.J., et al., Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro-oncology, 2011. 13(4): p. 410-416.

Varga, I., et al., Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathology & Oncology Research, 2012. 18(2): p. 413-420.

Matthews, R.T., et al., Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. Journal of Biological Chemistry, 2000. 275(30): p. 22695-22703.

Viapiano, M.S., R.T. Matthews, and S. Hockfield, A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. Journal of Biological Chemistry, 2003. 278(35): p. 33239-33247.

Aspberg, A., et al., The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein–protein interactions independent of carbohydrate moiety. Proceedings of the National Academy of Sciences, 1997. 94(19): p. 10116-10121.

Miura, R., et al., The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion. Journal of Biological Chemistry, 1999. 274(16): p. 11431-11438.

Seidenbecher, C.I., et al., Transcripts for secreted and GPI‐anchored brevican are differentially distributed in rat brain. European Journal of Neuroscience, 1998. 10(5): p. 1621-1630.

Yamada, H., et al., The brain chondroitin sulfate proteoglycan brevican associates with astrocytes ensheathing cerebellar glomeruli and inhibits neurite outgrowth from granule neurons. Journal of Neuroscience, 1997. 17(20): p. 7784-7795.

Miura, R., I.M. Ethell, and Y. Yamaguchi, Carbohydrate–protein interactions between HNK‐1‐reactive sulfoglucuronyl glycolipids and the proteoglycan lectin domain mediate neuronal cell adhesion and neurite outgrowth. Journal of neurochemistry, 2001. 76(2): p. 413-424.

Viapiano, M.S., et al., Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer research, 2005. 65(15): p. 6726-6733.

Nutt, C.L., R.T. Matthews, and S. Hockfield, Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. The Neuroscientist, 2001. 7(2): p. 113-122.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2020 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine